Neurosurgery
-
Randomized Controlled Trial Comparative Study Clinical Trial
Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema.
Continued elevations in Intracranial Pressure (ICP) following traumatic or ischemic compromise are known to cause markedly increased morbidity and mortality. Because of the side effects of barbiturates including hypotension and prolonged recovery time, the use of shorter-acting anesthetic agents to control ICP has been considered. Etomidate, when administered by continuous infusion, has been shown to decrease cerebral metabolism resulting in a secondary decrease in cerebral blood flow with minimal changes in cerebral perfusion pressure. ⋯ All patients also received dexamethasone 2 mg IV every six hours to prevent the adrenocortical insufficiency that might occur as a consequence of etomidate-induced suppression of cortisol synthesis. Intracranial pressure decreased (mean = 12mmHg) following the initiation of etomidate. Cardiac parameters remained unchanged (cardiac output 4.8 +/- .6 liters/min).(ABSTRACT TRUNCATED AT 250 WORDS)
-
Thoracic pedicle anatomy (interpedicular distance, transverse and sagittal pedicle widths, transverse and sagittal pedicle angles, and the distance from the axis of the pedicle to the axis of the transverse process) was assessed in 11 cadavers of elderly people. The cadaveric spines were extensively dissected to augment the accuracy of the measurements via caliper and goniometer. The results were compared with those of previous studies that assessed pedicle anatomy with computed tomography, direct measurement, and three-dimensional morphometry. ⋯ This relationship gradually changes as the thoracic spine is descended, so that at T12, the transverse process is 6.6 +/- 2.4 mm caudal to the pedicle. Crossover consistently occurs at the T6-T7 region. Although the transverse process is a reliable external landmark for the location of the pedicle in the lumbar spine, this relationship in the thoracic spine is variable and only moderately predictable.
-
Degenerative central lumbar stenosis has traditionally been considered to be a result of bony narrowing of the spinal canal. In two consecutive patients with degenerative central lumbar stenosis and complete myelographic blocks, the cauda equina was compressed by a thickened ligamentum flavum (cross-sectional area [CSA], > 150 mm2). This ligamentous stenosis occurred within bony canals of normal dimensions (anteroposterior diameter, interpediculate distance, interfacet distance, and CSA). ⋯ Excision of the thickened ligamentum flavum restored the dural sac to normal (CSA, 130-230 mm2), and both patients received relief from their symptoms. Unilateral laminotomy was used successfully to achieve bilateral ligamentectomy. Therefore, in a well-defined subgroup of patients with degenerative central lumbar stenosis, the dural sac can be decompressed by selective resection of the ligamentum flavum, and bilateral ligamentectomy can be performed via unilateral laminotomy.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
A multicenter, randomized, blinded, placebo-controlled trial was conducted to study the possible role of intracisternally administered fibrinolytic agent recombinant tissue plasminogen activator (rt-PA) in preventing delayed onset cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH). The target population was patients with ruptured saccular aneurysms causing severe SAH, placing them at high risk for vasospasm. Treatment consisted of a single 10 ml intraoperative injection of either vehicle buffer solution or rt-PA (1 mg/ml) into the opened basal subarachnoid cisterns immediately following aneurysm clipping. ⋯ However, there was a trend toward lesser degrees of vasospasm in the rt-PA treated group. The rates for no or mild, moderate, and severe vasospasm were 69%, 16% and 15% in the rt-PA treated group, versus 42%, 35% and 23% in the placebo group (P = 0.07). When only those patients with thick subarachnoid clots were considered at the treating centers, there was a 56% relative risk reduction of severe vasospasm in the rt-PA treated group, which was significant (P = 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)